Koselugo (Selumetinib Sulfate) Patent Expiration, LOE Window & CMS Spending

Koselugo (Selumetinib Sulfate) by AstraZeneca: FDA Orange Book core substance LOE 2028-03-13 (last listed 2032-11-19), 0 AB generics, $98.2M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN213756 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2028-03-13
Last Listed Patent or Exclusivity Date2032-11-19
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$98.2M
2024 Medicare Part D Spend$22.4M
2024 Medicaid Spend$75.8M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.